Sugi Predict

Sugi Predict / Compounds / SCHEMBL3402073

SCHEMBL3402073

SCHEMBL3402073

CC(C)(C)[Si](OCCOc1ccc(N)cn1)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.40
▸ POLB P06746 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ KEAP1 Q14145 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ BRCA1 P38398 1/20 0.36
▸ HBB P68871 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ PPARG P37231 3/20 0.34
▸ PPARA Q07869 3/20 0.34
▸ LTB4R Q15722 2/20 0.33
▸ SMYD2 Q9NRG4 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ LTA4H P09960 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9449004 0.80 GABRA5 (0.46) POLBMEN1KMT2AALDH1A1PPARG
SCHEMBL16973141 0.79 KDM4E (0.44) KDM4EPOLBRAB9AMEN1KMT2A
SCHEMBL29481761 0.79 KDM4E (0.44) KDM4EPOLBRAB9AMEN1KMT2A
SCHEMBL28723954 0.78 SMYD2 (0.35) KDM4ERAB9AALDH1A1LTB4RSMYD2
SCHEMBL17120961 0.76 SMN1; SMN2 (0.38) KDM4EHSD17B10PPARASMYD2CYP3A4
SCHEMBL23634035 0.75 KDM4E (0.50) KDM4EPOLBRAB9AMEN1KMT2A
SCHEMBL29837272 0.75 KDM4E (0.50) KDM4EPOLBRAB9AMEN1KMT2A
SCHEMBL21176568 0.75 SMYD2 (0.39) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL6617538 0.74 MAOB (0.49) RAB9APPARGSMYD2CYP3A4HTT
SCHEMBL22552303 0.74 CYP1A2 (0.37) KDM4EALDH1A1SMYD2CYP3A4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 — — US disclosed
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 — — EP disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 — — WO disclosed
US-5219863-A Treating hypertension and congestive heat failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-15 — — US disclosed
EP-0487252-A1 Quinoline and 1,5-Naphthyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them ZENECA LIMITED (GB) 1992-05-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 KDM4E 1741/4885POLB 4649/4885RAB9A 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.